Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -102.84% is 87% above its 5-year average of -775.16%, near the high end of its 5-year range (-17808.11%–1283.55%).
10.73% above its 12-month average of -115.20%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -224.38%.
NET PROFIT MARGIN
-102.84%
NET PROFIT MARGIN AVG TTM
-115.20%
NET PROFIT MARGIN AVG 3Y
-381.10%
NET PROFIT MARGIN AVG 5Y
-775.16%
NET PROFIT MARGIN AVG 10Y
-59.64%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+10.73%
CURRENT VS 3Y AVG
+73.02%
CURRENT VS 5Y AVG
+86.73%
CURRENT VS 10Y AVG
-72.45%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-39453.85%
vs the sector median at left
Verrica Pharmaceuticals Inc.
Market Cap
$72.32M
Net Profit Margin
-102.84%
TTM Avg
-115.20%
3Y Avg
-381.10%
5Y Avg
-775.16%
Market Cap
$72.83M
Net Profit Margin
-105.29%
TTM Avg
-106.48%
3Y Avg
-112.00%
5Y Avg
-95.88%
Market Cap
$73.27M
Net Profit Margin
-210.75%
TTM Avg
-289.10%
3Y Avg
-513.23%
5Y Avg
-2388.54%
Market Cap
$71.23M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-13227.36%
5Y Avg
-12286.00%
Market Cap
$70.63M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$69.88M
Net Profit Margin
-1.87%
TTM Avg
3.14%
3Y Avg
-4.53%
5Y Avg
-2.69%
Market Cap
$75.18M
Net Profit Margin
-55.03%
TTM Avg
-63.48%
3Y Avg
-81.34%
5Y Avg
-87.39%
Market Cap
$68.90M
Net Profit Margin
17.18%
TTM Avg
-64.27%
3Y Avg
-50.52%
5Y Avg
-660.79%
Market Cap
$75.95M
Net Profit Margin
-9.79%
TTM Avg
-5.93%
3Y Avg
-6.23%
5Y Avg
-32.51%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | $72.32M | -102.84% | -115.20% | -381.10% | -775.16% |
| MindWalk Holdings Corp. (HYFT)vs › | $72.83M | -105.29% | -106.48% | -112.00% | -95.88% |
| Hyperfine, Inc. (HYPR)vs › | $73.27M | -210.75% | -289.10% | -513.23% | -2388.54% |
| Gain Therapeutics, Inc. (GANX)vs › | $71.23M | 0.00% | 0.00% | -13227.36% | -12286.00% |
| Tiziana Life Sciences Ltd (TLSA)vs › | $70.63M | 0.00% | 0.00% | 0.00% | 0.00% |
| Champions Oncology, Inc. (CSBR)vs › | $69.88M | -1.87% | 3.14% | -4.53% | -2.69% |
| Pulmonx Corporation (LUNG)vs › | $75.18M | -55.03% | -63.48% | -81.34% | -87.39% |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | 17.18% | -64.27% | -50.52% | -660.79% |
| SkinHealth Systems Inc. (SKIN)vs › | $75.95M | -9.79% | -5.93% | -6.23% | -32.51% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | 163.32% | -34.49% | -63.76% | -75.19% |
Operating Margin
-33.6%
Net Profit Margin
-102.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -224.38% |
| 2026-03-31 | -192.75% |
| 2025-12-31 | -158.56% |
| 2025-09-30 | -1.91% |
| 2025-06-30 | 1.61% |
| 2025-03-31 | -283.28% |
| 2024-12-31 | -4709.88% |
| 2024-09-30 | 1283.55% |
| 2024-06-30 | -331.97% |
| 2024-03-31 | -531.39% |
| 2023-12-31 | -1238.13% |
| 2023-09-30 | -850.26% |
| 2023-06-30 | -6038.46% |
| 2023-03-31 | -17808.11% |
| 2022-12-31 | -8723.53% |
| 2022-09-30 | 1.00% |
| 2022-06-30 | -4751.40% |
| 2022-03-31 | -1965.20% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | -7.80% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
